Sarcoma Biology & 'Omics

(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT

(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES

(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM

(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL

(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT

(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS

(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES

(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE

(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.

(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.

(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE

(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE

(P 362) IDENTIFICATION OF A NOVEL INTERACTOR OF ENDOGENOUS SS18-SSX THROUGH MASS SPECTOMETRY-BASED ANALYSIS IN SYNOVIAL SARCOMA CELLS

(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)

(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS

(P 365) MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS

(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)

(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA

(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS

(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA

(P 370) SYNOVIAL SARCOMA; ROLE OF ADJUVANT CHEMOTHERAPY IN SURGICALLY TREATED PATIETNS WITH NO METASTASIS; A SEER STAT ANALYSIS.

(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY

(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA

(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?

(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN

(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS

(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL

(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS

(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY

(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA

(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES

(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA

(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.

(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA

(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE

(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA

(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM

(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT

(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.

(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ

(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.

(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA

(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS

(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS

(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES

(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY

(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA

(P 399) CRITICAL MOLECULAR PATHWAYS ASSOCIATED WITH DIFFERENT HISTOPATHOLOGY FEATURES AND DETAILED PATTERNS OF IMMUNE CELL INFILTRATES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)

(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4

(P 402) TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION

(P 403) THE IMPACT OF PATIENT, TUMOR, AND TREATMENT FACTORS ON SURVIVAL AND METASTASIS OUTCOMES IN PATIENTS WITH MYXOID LIPOSARCOMA

(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE

(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE

(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING

(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES

(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP

(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL

(P 411) A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.

(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE

(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS

(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT

(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA

(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS

(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS

(P 419) AGE ADJUSTED TRENDS IN PATIENTS WITH SYNOVIAL SARCOMA

(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.

(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS

(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS

(P 423) PRIMARY GLIOSARCOMA; IMPACT OF ADJUVANT CHEMO(RADIO)THERAPY ON SURVIVAL OUTCOME